Patents by Inventor Benjamin Wesley Trotter

Benjamin Wesley Trotter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aza-benzothiophene compounds as STING agonists
    Patent number: 11702430
    Abstract: Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: July 18, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael D. Altman, Brandon D. Cash, Jared N. Cumming, Duane E. DeMong, Andrew M. Haidle, James P. Jewell, Matthew A. Larsen, Min Lu, Ryan D. Otte, Brandon M. Taoka, Benjamin Wesley Trotter, Quang T. Truong
  • Cyclic di-nucleotide compounds as sting agonists
    Patent number: 11685761
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Za, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: June 27, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Brian M. Andresen, Frank Bennett, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Jongwon Lim, Min Lu, Benjamin Wesley Trotter, Wen-Lian Wu
  • Cyclic di-nucleotide compounds as sting agonists
    Patent number: 11466047
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: October 11, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Wen-Lian Wu, Jongwon Lim, Jared N. Cumming, Benjamin Wesley Trotter, Wonsuk Chang
  • Cyclic di-nucleotide compounds as sting agonists
    Patent number: 11453697
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: September 27, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Jared N. Cumming, Ryan D. Otte, Benjamin Wesley Trotter
  • Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
    Patent number: 11312772
    Abstract: Therapeutic combinations that comprise at least one antagonist of the Programmed Death 1 receptor (PD-1) and at least one benzo[b]thiophene compound that activates the Stimulator of Interferon Genes (STING) pathway are disclosed herein. Also disclosed is the use of such therapeutic combinations for the treatment of cancers.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: April 26, 2022
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Saso Cemerski, Jared N. Cumming, Johnny E. Kopinja, Samanthi A. Perera, Benjamin Wesley Trotter, Archie Ngai-Chiu Tse
  • Benzo[b]thiophene STING agonists for cancer treatment
    Patent number: 11285131
    Abstract: Therapies comprising administering at least one benzo[b]thiophene compound that activates the Stimulator of Interferon Genes (STING) pathway, and the use of such therapies in the treatment of cell-proliferation disorders such as cancer, are disclosed herein.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: March 29, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Saso Cemerski, Jared N. Cumming, Johnny E. Kopinja, Samanthi A. Perera, Benjamin Wesley Trotter, Archie Ngai-Chiu Tse
  • Cyclic Di-Nucleotide Compounds as STING Agonists
    Publication number: 20220033431
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • Cyclic Di-Nucleotide Compounds as STING Agonists
    Publication number: 20220033435
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds (I).
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • Cyclic Di-Nucleotide Compounds as STING Agonists
    Publication number: 20220024964
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds (I).
    Type: Application
    Filed: December 2, 2019
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
    Publication number: 20210206796
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Za, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Application
    Filed: December 17, 2018
    Publication date: July 8, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brian M. Andresen, Frank Bennett, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Jongwon Lim, Min Lu, Benjamin Wesley Trotter, Wen-Lian Wu
  • Combinations of PD-1 Antagonists and Benzo[b]thiophene STING Agonists for Cancer Treatment
    Publication number: 20210130466
    Abstract: Therapeutic combinations that comprise at least one antagonist of the Programmed Death 1 receptor (PD-1) and at least one benzo[b]thiophene compound that activates the Stimulator of Interferon Genes (STING) pathway are disclosed herein. Also disclosed is the use of such therapeutic combinations for the treatment of cancers.
    Type: Application
    Filed: July 30, 2018
    Publication date: May 6, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Saso CEMERSKI, Jared N. CUMMING, Johnny E. KOPINJA, Samanthi A. PERERA, Benjamin Wesley TROTTER, Archie Ngai-Chiu TSE
  • AZA-BENZOTHIOPHENE COMPOUNDS AS STING AGONISTS
    Publication number: 20210009608
    Abstract: Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brandon D. Cash, Jared N. Cumming, Duane E. DeMong, Andrew M. Haidle, James P. Jewell, Matthew A. Larsen, Min Lu, Ryan D. Otte, Brandon M. Taoka, Benjamin Wesley Trotter, Quang T. Truong
  • Benzo[b]thiophene STING Agonists for Cancer Treatment
    Publication number: 20200330427
    Abstract: Therapies comprising administering at least one benzo[b]thiophene compound that activates the Stimulator of Interferon Genes (STING) pathway, and the use of such therapies in the treatment of cell-proliferation disorders such as cancer, are disclosed herein.
    Type: Application
    Filed: July 30, 2018
    Publication date: October 22, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Saso CEMERSKI, Jared N. CUMMING, Johnny E. KOPINJA, Samanthi A. PERERA, Benjamin Wesley TROTTER, Archie Ngai-Chiu TSE
  • Sting agonist compounds
    Patent number: 10793557
    Abstract: Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 6, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brandon D. Cash, Matthew Lloyd Childers, Jared N. Cumming, Duane E. DeMong, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Matthew A. Larsen, Jongwon Lim, Min Lu, Ryan D. Otte, Benjamin Wesley Trotter
  • Cyclic di-nucleotide compounds as sting agonists
    Patent number: 10766919
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 8, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Rui Liang, Jongwon Lim, Hong Liu, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • Cyclic di-nucleotide compounds as STING agonists
    Patent number: 10759825
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 1, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, James P. Jewell, Jongwon Lim, Alan B. Northrup, Ryan D. Otte, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • Cyclic di-nucleotide compounds as STING agonists
    Patent number: 10738074
    Abstract: A class of polycyclic compounds of general formula (II), of general formula (II?), or of general formula (II?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: August 11, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong
  • Benzo[b]thiophene compounds as STING agonists
    Patent number: 10730849
    Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: August 4, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brandon D. Cash, Wonsuk Chang, Jared N. Cumming, Andrew M. Haidle, Timothy J. Henderson, James P. Jewell, Matthew A. Larsen, Rui Liang, Jongwon Lim, Min Lu, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Sriram Tyagarajan
  • Benzo[b]thiophene compounds as STING agonists
    Patent number: 10703738
    Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: July 7, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brandon D. Cash, Wonsuk Chang, Jared N. Cumming, Andrew M. Haidle, Timothy J. Henderson, James P. Jewell, Matthew A. Larsen, Rui Liang, Jongwon Lim, Min Lu, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Sriram Tyagarajan
  • CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT
    Publication number: 20200113924
    Abstract: Therapies comprising administering at least one cyclic dinucleotide compound that activates the Stimulator of Interferon Genes (STING) pathway, and the use of such therapies in the treatment of cell-proliferation disorders such as cancer, are disclosed herein.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 16, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Saso Cemerski, Jared N. Cumming, Lauren M. Flateland, Johnny E. Kopinja, Yanhong Ma, Samanthi A. Perera, Benjamin Wesley Trotter, Archie Ngai-Chiu Tse